@ARTICLE {10.3389 / fonc.2022.1100577作者={约翰逊,安娜·e, Raju Athul Raj雅各Aasems Hildebrandt,格哈德•C。},标题={病例报告:经典与中枢神经系统的参与毛细胞白血病的治疗vemurafenib},杂志={肿瘤学前沿},体积= {12}= {2023},URL = {//www.thespel.com/articles/1雷竞技rebat0.3389/fonc.2022.1100577}, DOI = {10.3389 / fonc.2022.1100577}, ISSN = {2234 - 943 x},文摘={毛细胞白血病(HCL)是一种罕见的成熟b细胞淋巴增殖性疾病,最常见的表现为典型的毛细胞白血病。这个实体的特征是一个懒惰的课程,由于BRAF V600E突变的存在。我们报告一个80岁的人的情况下历史的古典毛细胞白血病人出现疲劳、头晕、气短、视力模糊,头痛。他最初的诊断是9年前,他接受治疗与cladribine pentostatin,利妥昔单抗。检查显示白细胞计数升高与非典型淋巴细胞,贫血和血小板减少。外周血涂片证实HCL复发和大脑的磁共振成像(MRI)显示弥漫性,nonenhancing幕上的群众,infratentorial的大脑区域。他发起vemurafenib治疗,改善他的白细胞计数和复苏他的血小板计数和血红蛋白。重复MRI大脑的3个月后显示病变完全消失。Vemurafenib停止6个月后,骨髓活检显示没有证据表明剩余毛细胞白血病。 There have only been limited reports of HCL involvement in the central nervous system in the literature. Due to the rarity of the condition, it is not clear which treatments can be effective for intracranial disease control. Our report shows the successful use of vemurafenib, resulting in complete remission of relapsed HCL with CNS involvement.} }